Shandong Wohua Pharmaceutical Co., Ltd. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Wohua Pharmaceutical Co., Ltd. with three other
companies in this sector in China:
Zhejiang Starry Pharmaceutical Co Ltd
sales of 710.94 million Chinese Renmimbi [US$103.61 million]
of which 84%
was Contrast Agent),
Hunan Fangsheng Pharmaceutical Co Ltd
(720.77 million Chinese Renmimbi [US$105.04 million]
of which 88%
was Pharmaceutical Manufacturing), and
Shanghai Fudan Forward S&T Co Ltd
(735.73 million Chinese Renmimbi [US$107.22 million]
of which 64%
During the year ended December of 2017, sales at
Shandong Wohua Pharmaceutical Co., Ltd. were 726.65 million Chinese Renmimbi (US$105.89 million).
increase of 29.1%
versus 2016, when the company's sales were 562.80 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shandong Wohua Pharmaceutical Co., Ltd.
(and since 2012, sales have increased a total of 247%).
Sales of Medical Industry saw an increase
29.2% in 2017, from
560.84 million Chinese Renmimbi to 724.66 million Chinese Renmimbi.
Not all segments of Shandong Wohua Pharmaceutical Co., Ltd. experienced an increase in sales in 2017:
sales of Medical Business fell 0.6% to 1.99 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).